SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Providing guidance to the NHS: The Scottish Medicines Consortium and the National Institute for Clinical Excellence compared
2 references·2 citing·15 second hop
Providing guidance to the NHS: The Scottish Medicines Consortium and the National Institute for Clinical Excellence compared (2005)Providing guidance to the NHS: The Scotti…Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle (2004)Inclusion of cost effectivene…Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis (2004)Does NICE have a cost‐effecti…Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia (2016)Health benefit assessment of …Nasty or Nice? A Perspective on the Use of Health Technology Assessment in the United Kingdom (2009)Nasty or Nice? A Perspective …Cost-Effectiveness in Health and Medicine (1996)National Institute for Clinical Excellence and its value judgments (2004)Methods for the Economic Evaluation of Health Care Programmes (2005)The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies (1999)Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold (2008)Key principles for the improved conduct of health technology assessments for resource allocation decisions (2008)International survey on willingness‐to‐pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? (2009)Cost-Effectiveness Analysis and the Consistency of Decision Making (2001)Health Economic Guidelines—Similarities, Differences and Some Implications (2001)Theory versuspractice: a review of ?willingness-to-pay? in health and health care (2001)Measuring Preferences for Cost-Utility Analysis (2007)Coverage with Evidence Development, Only in Research, Risk Sharing, or Patient Access Scheme? A Framework for Coverage Decisions (2012)Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC—Does the Presence of an Explicit Threshold Affect the ICER Proposed? (2018)A Coefficient of Agreement for Nominal Scales (1960)Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions (2009)
this work references cited by second hop

References

  • 2004Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis710 cited
  • 2004Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle194 cited

Cited by

  • 2016Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia53 cited
  • 2009Nasty or Nice? A Perspective on the Use of Health Technology Assessment in the United Kingdom52 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work